Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

231.11
BATS BZX Real-Time Price
As of 3:04pm ET
 -6.68 / -2.81%
Today’s Change
195.50
Today|||52-Week Range
322.68
-26.04%
Year-to-Date
Dow 30 Stock Roundup: Nike Earnings Impress, Boeing Wins $8B Saudi Order
11:03am / Zacks.com - Paid Partner Content
5 Biotech Stocks to Watch as Interest in NASH Increases
Sep 22 / Zacks.com - Paid Partner Content
Are Hedge Funds Technically Wrong?
8:01am / TheStreet.com - Paid Partner Content
Is Galectin The Next Takeover Target for the Biotech World?
Sep 22 / Zacks.com - Paid Partner Content
Are Hedge Funds Technically Wrong?
Sep 28 / TheStreet.com - Paid Partner Content
Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan
Sep 22 / TheStreet.com - Paid Partner Content
These 3 Stocks Tripled in 12 Months
Sep 28 / MotleyFool.com - Paid Partner Content
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sep 21 / Zacks.com - Paid Partner Content
Pfizer (PFE) to Stay Together as a Single Company After All
Sep 27 / Zacks.com - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Ruane Cunniff Cuts Allergan, Berkshire, IBM
Sep 26 / GuruFocus News - Paid Partner Content
Allergan Buys NASH Therapy Maker Tobira at Huge Premium
Sep 21 / Zacks.com - Paid Partner Content
Read Scraps Pfizer Break-up As Megadeals Escape Its Grasp
Sep 26 / TheStreet.com - Paid Partner Content
Why Did Tobira Therapeutics (TBRA) Stock Skyrocket 720% Today?
Sep 20 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Deutsche Bank, Apple, Therapeutics, Allergan and G...
Sep 26 / Zacks.com - Paid Partner Content
Why DTS, SolarCity, and Tobira Therapeutics Jumped Today
Sep 20 / MotleyFool.com - Paid Partner Content
Allergan Gets FDA Approval for New Line of Breast Implants
Sep 26 / Zacks.com - Paid Partner Content
Why Tobira Therapeutics Inc Was an Overnight Octuple
Sep 20 / MotleyFool.com - Paid Partner Content
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep 26 / Zacks.com - Paid Partner Content
Sarepta jumps after drugs regulator boost
Sep 20 / FT.com - Paid Partner Content
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
Sep 24 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Sep 16 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: Microsoft Rewards Shareholders; GE Wins $1.9B Nuclear Power Con...
Sep 23 / Zacks.com - Paid Partner Content
Stock Market News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
ETFs in Focus on the Nasdaq Rally
Sep 23 / Zacks.com - Paid Partner Content
Company News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
Allergan/Adamas Launch New Dosage Strengths of Namzaric
Sep 23 / Zacks.com - Paid Partner Content
Allergan to Buy Vitae Pharma to Boost Dermatology Suite
Sep 15 / Zacks.com - Paid Partner Content
US politicians lament inaction over price-gouging drug companies
Sep 23 / FT.com - Paid Partner Content
Coach slips on 'unhealthy manner' warning
Sep 14 / FT.com - Paid Partner Content
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Sep 23 / Zacks.com - Paid Partner Content
Bayer Monsanto deal requires jumbo financing
Sep 14 / FT.com - Paid Partner Content
Allergan's Vitae buy could spark more interest in Kadmon
Sep 23 / TheStreet.com - Paid Partner Content
'Middlemen' under the spotlight in EpiPen furore
Sep 09 / FT.com - Paid Partner Content
Wallace Weitz's Largest 2nd-Quarter Trades
Sep 22 / GuruFocus News - Paid Partner Content
CEO of Botox maker vows to limit price hikes
Sep 07 / CNNMoney.com
The Good, the Bad and the Ugly in Today's Market
Sep 22 / TheStreet.com - Paid Partner Content